Industry hits jackpot in Brazil – quicker clinical trial approvals
This article was originally published in Scrip
Executive Summary
Interfarma, which represents the R&D-based pharmaceutical industry in Brazil, has thanked the national medicines regulator, ANVISA, for its recent proposals to improve the clinical trial application procedure. If enacted, the measures could attract more clinical trials to the country and shave up to 90 days off the approval process for 80% of trials, says the organisation.